Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyPrime time for immune-checkpoint targeted therapy at ASCO 2015DNA repair targeted therapy: The past or future of cancer treatment?Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerDevelopment of cell-cycle checkpoint therapy for solid tumorsTargeting the Checkpoint to Kill Cancer CellsPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerA phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyMolecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Translational and clinical implications of the genetic landscape of prostate cancer.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Cell cycle proteins as promising targets in cancer therapyCyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.DNA replication stress and cancer: cause or cure?Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Single versus combination immunotherapy drug treatment in melanoma.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Cell Cycle Regulation and Melanoma.Targeting the ATR-CHK1 Axis in Cancer TherapyPD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.Targeted agents and immunotherapies: optimizing outcomes in melanoma.The cell cycle checkpoint inhibitors in the treatment of leukemias.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
P2860
Q26745686-CFEA13E7-F27D-4DBF-8789-066C8A3D7831Q26747711-85B9E6BB-AF65-453E-8039-0D5E26D1EFEDQ26768679-5D4F3E8D-C278-4D44-9759-EF790D41F355Q26769870-92FBE8DD-61EA-4FFC-8555-7C8D674D4DC0Q26776513-9F3729B9-1F27-4111-9879-10344F1A2790Q26781187-84B692EE-4392-4EAA-B5A5-91AE157979B1Q26795781-B61F1853-CE75-4469-A6A0-9239C122E725Q28066320-15CB35A7-FC69-4F3F-B7C9-E586A61C9462Q28077848-EE7969B6-9ACD-4DD4-B85E-EFC8469E4F9DQ28078268-9F6BCD79-C6AD-4740-8177-4E7FADC6EB00Q33431248-6AF8FF77-7A0F-4A68-8815-B51A92E7E268Q33439342-79D93ACE-E734-40A8-BD61-92D4DB914BA0Q34543038-755FC80C-0521-4EF1-853B-3CEFC3DC5C1EQ35232784-1A422A32-D0F5-4465-87F7-62779424DBA1Q36261341-4CC001BC-C5E5-49EB-9AFE-5D889AB54AEBQ36371654-93E1C9D2-7D3F-47F9-BC06-B384ECAC6F3BQ36545701-106861CC-6D99-4EBD-B62B-7C9726C293E6Q36546455-78878FE6-3794-4120-BB71-0CA6CD0047B1Q36738836-E54F7A2E-5EF6-4C29-9FD8-1B6868679939Q36739002-902A70E4-4CDE-48A1-973E-C2723B822098Q36838392-92BDD5F8-1AD9-4A18-B965-501C211EB866Q36898404-FE9FDBA5-27E6-4A7D-B305-B9E652DD7DFBQ37176648-8CE9A6EA-0A18-4BD4-87FA-CA4201AFD949Q37270512-DB5A33D7-E2BE-4476-987D-8671D865DE1CQ37555069-83F682DD-40B9-47D5-8A9D-0BEB30B99EB1Q37634102-9F093797-9138-4C7D-A7B6-45289834A615Q37693690-747066BF-C220-4D6D-9954-CA49F0027F10Q38544813-195ADFC9-1EF3-4E8E-82FC-E680598DE502Q38608688-9574CE9B-9978-41A8-9A73-97A20495162DQ38652528-17E1630B-8768-4D49-9618-E9671661FE87Q38660811-665E4C83-A5BA-4999-8E62-17F0AD1A6A0CQ38661099-E1B806B8-A2D0-4551-AD2F-66F4C945BC33Q38806243-4FBDD1AB-807F-4ACE-AFAF-FE1C426F247EQ38815527-A5246C39-36A7-4941-8508-05365DA041F3Q38817102-BD0B8263-D5E8-4257-A390-C731463D6A37Q38838649-724C10C4-69C3-40D5-B67B-4C3DD10E8E08Q38839130-1A114803-E796-45FE-B707-9B73AE13BE7EQ38856722-95D45F81-FE6E-41D9-9AB9-E43476B8D4DAQ38868502-02959930-79F7-43D2-9C15-F580AC313048Q39069585-77F4C64B-48AB-4913-AB1C-0CFEDC4145FB
P2860
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@ast
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@en
type
label
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@ast
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@en
prefLabel
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@ast
Phase I dose-escalation trial ...... ts with advanced solid tumors.
@en
P2093
P50
P356
P1476
Phase I dose-escalation trial ...... nts with advanced solid tumors
@en
P2093
Alan P Venook
Christopher Sorge
David Mendelson
David Parry
Gregory Springett
Jennifer A Grabowsky
Jonathan Strosberg
Jonathan W Goldman
Lee S Rosen
Michelle T Ashworth
P304
P356
10.1200/JCO.2014.57.5027
P407
P577
2015-01-20T00:00:00Z